These data corroborate results observed in previous studies that IL-13 can improve neurological deficits and brain damage after stroke (up to 14 days) [47, 48] and shows that this improvement may persists for longer times post-stroke (up to 35 days post-stroke). The gene discussed is IL13; the disease is stroke disorder.